Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AC2993 LAR: AMLN started a double-blind, placebo-controlled U.S. Phase II trial of AC2993 LAR in up to 100 patients to treat Type II diabetes. AC2993 LAR uses M

Amylin Pharmaceuticals Inc. (AMLN), San Diego, Calif.
Product: AC2993 LAR
Business: Metabolic
Therapeutic

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE